Evolent Q2 FY26 net loss narrows to $28.36 million; revenue rises 46.84% to $652.52 million

Reuters2026/08/06 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evolent Health posted Q2 2026 revenue of USD 652.52 million, up 46.85% from a year earlier; net loss narrowed to USD 28.36 million.
Loss per share improved to USD 0.25; net loss margin tightened by 7.2 percentage points to 4.3%.
Non-GAAP adjusted EBITDA fell to USD 28.05 million from USD 37.55 million; adjusted EBITDA margin slid 4.2 percentage points to 4.3%.
Preparing to launch an Oncology Performance Suite partnership covering about 1.5 million lives; targets about USD 300 million annualized revenue.
Raised 2026 revenue outlook to USD 2.6 billion-USD 2.7 billion; tightened non-GAAP adjusted EBITDA view to USD 120 million-USD 135 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evolent Q2 FY26 net loss narrows to $28.36 million; revenue rises 46.84% to $652.52 million

You may also like

Crypto prices